Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: a budget impact analysis on the basis of clinical trial and real-world data

References

• Aapro M, Boccia R, Leonard R, et al. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer. 2017;25(11):3295–3304.
   PubMed Web of Science ®Google Scholar
• Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111–v118.
   PubMed Web of Science ®Google Scholar
• Chang J. Chemotherapy dose reduction and delay in clinical practice. Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer. 2000;36(Suppl 1):11–14.
   Google Scholar
• Khan S, Dhadda A, Fyfe D, et al. Impact of neutropenia on delivering planned chemotherapy for solid tumours. Eur J Cancer Care. 2008;17(1):19–25.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer. 2008;16(11):1299–1309.
   PubMed Web of Science ®Google Scholar
• Freyer G, Scotte F, Borget I, et al. Clinical burden caused by hospitalization for febrile neutropenia in France in 2010–2011: an analysis of the PMSI database. Bull Cancer. 2016;103(6):552–560.
   PubMed Web of Science ®Google Scholar
• Vainchtock A, Cohen S, Zaleski I. PCN84. Analysis of public and private hospital databases (PMSI) 2010/2011 to estimate the frequency and associated costs for febrile neutropenia in France. Value Health. 2013;16(7):A406.
   Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–3167.
   PubMed Web of Science ®Google Scholar
• Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.
   PubMed Web of Science ®Google Scholar
• Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198–4214.
   PubMed Web of Science ®Google Scholar
• Wait S, Han D, Muthu V, et al. Towards sustainable cancer care: Reducing inefficiencies, improving outcomes—a policy report from the All.Can initiative. J Cancer Policy. 2017;13:47–64.
   Web of Science ®Google Scholar
• UK National Health Service. What is a biosimilar medicine. NHS England and NHS improvement; 2019. Available from: https://www.england.nhs.uk/wp-content/uploads/2019/05/what-is-a-biosimilar-medicine-guide-v2.pdf
   Google Scholar
• Cole A, Lundqvist A, Lorgelly P, et al. Improving efficiency and resource allocation in future cancer care. London (UK): Office of Health Economics; 2016. Available from: https://www.ohe.org/publications/improving-efficiency-and-resource-allocation-future-cancer-care
   Google Scholar
• European Medicines Agency. Nyvepria - summary of product characteristics (placeholder) 2020 [cited 2020 October 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/nyvepria-epar-product-information_en.pdf
   Google Scholar
• Moosavi S, Borema T, Ewesuedo R, et al. PF-06881894, a proposed biosimilar to pegfilgrastim, versus US-licensed and EU-approved pegfilgrastim reference products (Neulasta®): pharmacodynamics, pharmacokinetics, immunogenicity, and safety of single or multiple subcutaneous doses in healthy volunteers . Adv Ther. 2020;37(7):3370–3391.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task Force. Value Health. 2014;17(1):5–14.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Pharmacoeconomics. 2013;31(5):361–367.
   PubMed Web of Science ®Google Scholar
• Fust K, Li X, Maschio M, et al. Cost-effectiveness analysis of prophylaxis treatment strategies to reduce the incidence of febrile neutropenia in patients with early-stage breast cancer or non-Hodgkin lymphoma. Pharmacoeconomics. 2017;35(4):425–438.
   PubMed Web of Science ®Google Scholar
• Trautman H, Szabo E, James E, et al. Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective. J Manag Care Spec Pharm. 2019;25(1):94–101.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Ziextenzo - summary of product characteristics 2019 [cited 2020 October 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/ziextenzo-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Lonquex - summary of product characteristics 2013 [cited 2020 October 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/lonquex-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Fulphila - summary of product characteristics 2018 [cited 2020 October 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/fulphila-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Pelgraz - summary of product characteristics 2018 [cited 2020 October 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/pelgraz-epar-product-information_en.pdf
   Google Scholar
• Ministère des Solidarités et de la Santé. NEUPOGEN 30 MU (0,3 mg/mL), solution injectable - résumé des caractéristiques du produit 2019 [cited 2020 October 20]. Available from: http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=69225686&typedoc=R
   Google Scholar
• European Medicines Agency. Nivestim - summary of product characteristics 2010 [cited 2020 October 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/nivestim-epar-product-information_en.pdf
   Google Scholar
• Ministère des Solidarités et de la Santé. GRANOCYTE 34 millions UI/ml, poudre et solvant pour solution injectable/perfusion en seringue préremplie - résumé des caractéristiques du produit 2018 [cited 2020 October 20]. Available from: http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=65066667&typedoc=R
   Google Scholar
• Open Innovation Program; OIP Healthcare. Synapps drug market. Extract Oct 2020.
   Google Scholar
• L'Assurance Maladie. Base des Medicaments et Informations Tarifaires 2021 [cited 2021 January 26]. Available from: http://www.codage.ext.cnamts.fr/codif/bdm_it/index_presentation.php?p_site=AMELI
   Google Scholar
• L'Assurance Maladie. Nomenclatures: NGAP and LPP 2020 [cited 2020 November 19]. Available from: https://www.ameli.fr/infirmier/exercice-liberal/facturation-remuneration/nomenclatures-ngap-lpp/nomenclatures-ngap-lpp
   Google Scholar
• Coldefy M, Com-Ruelle L, Lucas-Gabrielli V, et al. Les distances d’accès aux soins en France métropolitaine au 1er janvier 2007 2011 [cited 2020 October 13]. Available from: https://www.irdes.fr/Publications/Rapports2011/rap1838.pdf
   Google Scholar
• IRDES. RAPPORTS n° 550 et 551 (biblios n° 1838 et 1839) 2020 [cited 2020 November 19]. Available from: https://www.irdes.fr/EspaceRecherche/BiblioResumeEtSommaire/2011/Rapport1838.htm
   Google Scholar
• Tilleul PR, Rodgers-Gray BS, Edwards JO. Introduction of biosimilar pegfilgrastim in France: economic analysis of switching from originator. J Oncol Pharm Pract. 2020. DOI:https://doi.org/10.1177/1078155220962208
   Google Scholar
• Laribi K, Badinand D, Janoray P, et al. Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study. Support Care Cancer. 2019;27(11):4283–4292.
   PubMed Web of Science ®Google Scholar
• Roché H, Eymard J-C, Radji A, et al. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study). BMC Cancer. 2018;18(1):1127.
   PubMed Web of Science ®Google Scholar
• Cornes P, Gascon P, Chan S, et al. Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia. Adv Ther. 2018;35(11):1816–1829.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices. JMCP. 2007;13(4):337–348.
   PubMed Web of Science ®Google Scholar
• Tan H, Tomic K, Hurley D, et al. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin. 2011;27(1):79–86.
   PubMed Web of Science ®Google Scholar
• Henk H, Becker L, Tan H, et al. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses. J Med Econ. 2013;16(1):160–168.
   PubMedGoogle Scholar
• Almenar D, Mayans J, Juan O, et al. Pegfilgrastim and daily granulocyte colony‐stimulating factor: patterns of use and neutropenia‐related outcomes in cancer patients in Spain–results of the LEARN Study. Eur J Cancer Care). 2009;18(3):280–286.
   PubMed Web of Science ®Google Scholar
• Naeim A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer. 2013;13(1):1–10.
   PubMed Web of Science ®Google Scholar
• Mitchell S, Li X, Woods M, et al. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract. 2016;22(5):702–716.
   PubMed Web of Science ®Google Scholar
• Phillips J, Ritter S, Starner C, et al. Filgrastim (Neupogen) and pegfilgrastim (Neulasta): cost analysis and utilization management opportunity assessment. J Manag Care Pharm. 2012;18:176–177.
   Google Scholar
• IMS Institute for Healthcare Informatics. Assessing Biosimilar Uptake and Competition in European Markets. 2014.
   Google Scholar
• French Population Census [cited Dec 19, 2019]. Available from: https://www.insee.fr/en/metadonnees/source/serie/s1321
   Google Scholar
• European Commission. ECIS - European Cancer Information System 2020 [cited 2020 October 18]. Available from: https://ecis.jrc.ec.europa.eu/
   Google Scholar
• Worldometer. France Population 2020 [cited 2020 October 13]. Available from: https://www.worldometers.info/world-population/france-population/
   Google Scholar
• André S, Taboulet P, Elie C, et al. Febrile neutropenia in French emergency departments: results of a prospective multicentre survey. Crit Care. 2010;14(2):R68.
   PubMed Web of Science ®Google Scholar